Skip to main content

Benitec Biopharma (NASDAQ: BNTC) — Company Overview, News & Financial Data

Benitec Biopharma  logo
BNTC Benitec Biopharma
Benitec Biopharma  primary media
Company profile

Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC) is a dynamic biotechnology firm focused on the development of genetic medicines. Benitec's innovative approach leverages its proprietary gene-silencing technology, called DNA-directed RNA interference (ddRNAi), to create therapies aimed at treating chronic and life-threatening diseases. The company's pipeline includes projects targeting conditions such as hepatitis B, age-related macular degeneration, and oculopharyngeal muscular dystrophy, showcasing its commitment to addressing unmet medical needs through groundbreaking research. With a mission to pioneer the next generation of genetic medicines, Benitec strives to improve patient outcomes and alter the course of disease with its cutting-edge technologies and therapies.

Snapshot

Public USOwnership
1997Year founded
16Employees
California, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
United States

Products and/or services of Benitec Biopharma

  • BB-301 for oculopharyngeal muscular dystrophy, a gene-silencing therapy aiming to reduce the production of toxic proteins causing muscle weakness.
  • Gene therapy projects targeting chronic and life-threatening conditions, leveraging DNA-directed RNA interference technology.
  • BB-103 for hepatitis B, a treatment designed to disrupt the viral replication process.
  • Collaborations with academic and biomedical entities to develop innovative gene therapies for various diseases.
  • Research on ddRNAi technology, a proprietary platform for developing treatments targeting genetic disorders.
  • Development services for third-party gene therapy products, including custom gene-silencing constructs and licensing of proprietary technologies.

Benitec Biopharma executive team

  • Jerel A. BanksExecutive Chairman & CEO
  • Megan Joan BostonCFO & Secretary
  • Sophie MukadamChief Operating Officer
  • Michael GrahamHead of Discovery & Founding Scientist
  • Claudia KlothSenior Vice President of Manufacturing

Recent announcements

What Benitec Biopharma (BNTC) has told the market, newest first.

Dividend history

Dividends per share paid by Benitec Biopharma , by financial year.

Benitec Biopharma dividends per share by financial year
Financial yearInterimFinalSpecialTotal
FY2018$0.7650——$0.7650

Key financials

Reported results for Benitec Biopharma , in AUD.

Market cap
294M
Revenue (TTM)
7K
P/E ratio
—
EPS (diluted, TTM)
-1.0
Dividend yield
—
Profit margin
0.0%
Benitec Biopharma annual revenue and income
Fiscal year endRevenueOperating incomeNet income
0-51.2M-45.5M
0-41.8M-37.9M
216K-22.5M-21.8M
75K-19.1M-19.6M